Table 1.
Phenotypic features of peripheral blood and spleen leukocytes from T. cruzi-infected cynomolgus macaques.
| Cell Phenotypes | Peripheral Blood | Spleen | ||||||
|---|---|---|---|---|---|---|---|---|
| NI | CCC(-) | CCC(+) | CCC(++) | NI | CCC(-) | CCC(+) | CCC(++) | |
| Innate Immunity | ||||||||
| CD14+CD32+ (MFI) | 304.8 ± 41.8 | 411.3 ± 59.7 | 445.8 ± 99.8 | 320.2 ± 72.7 | 459.4 ± 55.2 | 559.5 ± 67.8 | 475.3 ± 73.7 | 490.8 ± 19.2 |
| CD14+CD64+ (MFI) | 65.6 ± 9.0 | 92.1 ± 39.9 | 78.0 ± 21.0 | 41.8 ± 5.9 | 89.8 ± 11.2 | 102.6 ± 22.6 | 95.7 ± 26.1 | 91.8 ± 26.1 |
| CD3-CD16+ | 9.0 ± 2.0 | 4.9 ± 1.5 | 11.1 ± 3.2 | 12.4 ± 4.5 | 16.6 ± 4.6 | 12.3 ± 2.7 | 16.3 ± 5.9 | 15.8 ± 4.8 |
| %CD16+CD56- | 14.1 ± 3.4 | 5.3 ± 1.4a,c,d | 10.8 ± 2.6 | 16.3 ± 6.0 | 27.7 ± 7.7 | 21.8 ± 5.0 | 28.9 ± 11.7 | 34.5 ± 6.8 |
| %CD16+CD56+ | 5.9 ± 1.4 | 6.1 ± 3.8 | 7.6 ± 2.9 | 10.8 ± 4.4 | 3.4 ± 0.4 | 5.9 ± 1.3 | 4.4 ± 0.4 | 4.3 ± 0.4 |
| %CD16-CD56+ | 6.2 ± 0.6 | 6.4 ± 1.2 | 6.9 ± 2.4 | 5.2 ± 1.1 | 5.5 ± 0.3 | 7.7 ± 0.9 | 7.2 ± 1.2 | 4.1 ± 0.5 |
| %CD16+CD54+ | 8.8 ± 1.7 | 15.6 ± 4.0 | 7.6 ± 3.8 | 8.3 ± 2.7 | 16.1 ± 2.4 | 26.5 ± 4.5 | 12.9 ± 5.7 | 13.5 ± 1.8 |
| %CD16+CD69+ | 35.5 ± 5.9 | 22.2 ± 3.1a,c | 34.8 ± 6.0 | 26.5 ± 7.5 | 32.3 ± 2.8 | 32.3 ± 4.1 | 43.2 ± 8.7 | 29.6 ± 9.3 |
| %CD16+GranA+ | 16.6 ± 3.6 | 14.3 ± 2.8a | 38.1 ± 11.2a,b | 40.3 ± 9.6a,b | 22.0 ± 2.5 | 21.1 ± 3.1 | 33.0 ± 7.8 | 37.5 ± 5.3 |
| %CD16+GranB+ | 45.7 ± 3.9 | 36.1 ± 5.8 | 45.4 ± 12.4 | 47.0 ± 9.2 | 59.1 ± 3.6 | 34.5 ± 3.0 | 52.6 ± 6.1 | 53.1 ± 6.6 |
| %CD16+Perf+ | 46.1 ± 6.6 | 37.8 ± 4.0 | 52.0 ± 9.1 | 46.9 ± 6.5 | 60.9 ± 3.7 | 31.9 ± 2.4 | 54.9 ± 5.4 | 52.8 ± 6.2 |
| CD3+CD16+ | 3.5 ± 0.4 | 4.2 ± 0.1 | 2.6 ± 0.8b | 3.2 ± 0.7b | 7.3 ± 0.9 | 8.2 ± 0.6 | 7.1 ± 1.2 | 4.7 ± 0.4 |
| % CD3+CD16+CD56- | 2.6 ± 0.7 | 0.9 ± 0.2a | 0.9 ± 0.1 | 1.7 ± 0.6 | 5.0 ± 0.6 | 4.6 ± 1.2 | 5.2 ± 0.6 | 5.5 ± 1.7 |
| % CD3+CD16+CD56+ | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.1 ± 0.0 | 0.4 ± 0.2 | 1.3 ± 0.2 | 1.2 ± 0.2 | 1.5 ± 0.6 | 1.2 ± 0.3 |
| % CD3+CD16-CD56+ | 3.6 ± 0.3 | 5.8 ± 0.3a,c,d | 3.6 ± 0.7 | 2.7 ± 0.4 | 6.3 ± 0.7 | 6.9 ± 0.9 | 4.9 ± 0.4 | 3.8 ± 1.1 |
| Adaptive Immunity | ||||||||
| CD3+ | 62.0 ± 3.4 | 60.5 ± 3.1 | 58.1 ± 7.0 | 64.0 ± 5.2 | 54.6 ± 4.6 | 64.1 ± 2.6 | 51.6 ± 6.7 | 51.1 ± 6.0 |
| CD3+CD4+ | 32.7 ± 2.5 | 23.0 ± 2.8a | 28.7 ± 1.3d | 32.7 ± 1.2b | 16.2 ± 1.8 | 13.7 ± 2.5 | 12.9 ± 1.6 | 16.7 ± 3.3 |
| CD3+CD8+ | 31.1 ± 3.3 | 37.4 ± 5.7 | 28.7 ± 8.7 | 35.9 ± 5.0 | 40.2 ± 4.3 | 38.1 ± 7.7 | 36.0 ± 5.7 | 33.6 ± 6.1 |
| %CD3+CD54+ | 1.0 ± 0.1 | 2.7 ± 0.9a | 2.3 ± 1.0 | 1.4 ± 0.3 | 5.3 ± 0.8 | 4.6 ± 0.5 | 6.2 ± 1.6 | 3.3 ± 0.7 |
| %CD4+CD54+ | 1.4 ± 0.2 | 3.7 ± 1.2a | 17.8 ± 15.7 | 6.9 ± 1.4 | 7.5 ± 1.0 | 9.5 ± 1.9 | 11.9 ± 4.4 | 6.4 ± 1.4 |
| %CD8+CD54+ | 1.2 ± 0.2 | 2.9 ± 1.5a | 8.5 ± 4.2a | 2.9 ± 1.0a | 3.9 ± 0.5 | 4.1 ± 0.9 | 4.2 ± 0.9 | 3.2 ± 0.7 |
| %CD3+CD69+ | 9.6 ± 1.9 | 8.5 ± 2.8 | 9.7 ± 1.9 | 5.7 ± 1.6 | 26.1 ± 2.8 | 26.5 ± 3.2 | 36.0 ± 3.0 | 31.7 ± 4.2 |
| %CD4+CD69+ | 4.2 ± 1.0 | 4.5 ± 1.5 | 4.3 ± 1.5 | 3.2 ± 0.7 | 25.5 ± 2.1 | 30.0 ± 3.6 | 34.6 ± 1.6 | 28.7 ± 2.7 |
| %CD8+CD69+ | 23.1 ± 4.0 | 16.1 ± 2.5 | 26.3 ± 4.7b,d | 16.1 ± 2.5 | 24.3 ± 2.5 | 27.0 ± 5.2 | 36.3 ± 2.1 | 30.2 ± 4.9 |
| %CD3+HLA-DR+ | 3.1 ± 0.7 | 4.2 ± 0.7a | 5.6 ± 1.3a,d | 3.0 ± 0.3 | 6.6 ± 0.8 | 9.0 ± 0.6 | 8.3 ± 1.1 | 11.0 ± 1.4 |
| %CD4+HLA-DR+ | 3.1 ± 0.4 | 4.6 ± 1.3 | 3.9 ± 0.6 | 2.2 ± 0.2c,b | 18.1 ± 1.7 | 20.6 ± 5.3 | 19.5 ± 4.4 | 17.4 ± 3.0 |
| %CD8+HLA-DR+ | 5.6 ± 1.8 | 7.7 ± 1.8 | 7.8 ± 1.4 | 6.5 ± 1.6 | 6.8 ± 0.9 | 7.3 ± 1.8 | 6.3 ± 1.9 | 10.4 ± 1.6 |
| %CD3+CCR5+ | 26.4 ± 4.6 | 29.2 ± 7.5 | 28.7 ± 2.7 | 20.6 ± 5.9 | 33.0 ± 4.0 | 39.6 ± 9.1 | 29.1 ± 6.0 | 30.0 ± 5.9 |
| %CD4+CCR5+ | 19.7 ± 2.9 | 24.8 ± 4.6 | 16.3 ± 1.2 | 17.5 ± 3.8 | 34.6 ± 2.7 | 48.7 ± 6.8 | 30.2 ± 2.8 | 29.7 ± 4.9 |
| %CD8+CCR5+ | 31.6 ± 5.5 | 34.5 ± 7.3 | 38.0 ± 4.5 | 25.3 ± 7.5 | 30.6 ± 3.7 | 41.8 ± 8.0 | 25.8 ± 5.5 | 23.2 ± 4.8 |
| %CD8+GranA+ | 6.9 ± 4,5 | 9.1 ± 1.2a | 15.8 ± 2.8a,b | 15.9 ± 3.5a,b | 11.0 ± 1.9 | 11.2 ± 2.6 | 14.9 ± 1.7 | 17.5 ± 1.9 |
| %CD8+GranB+ | 52.6 ± 7.2 | 58.2 ± 11.9 | 49.0 ± 9.1 | 55.9 ± 7.4 | 43.6 ± 5.5 | 43.6 ± 8.5 | 38.8 ± 8.7 | 46.8 ± 3.8 |
| %CD8+Perf+ | 56.2 ± 7.9 | 69.1 ± 11.0 | 62.7 ± 8.1 | 63.3 ± 8.0 | 58.4 ± 6.6 | 61.3 ± 9.6 | 58.1 ± 9.1 | 57.6 ± 6.1 |
| %CD4+CD25++ | 3.5 ± 0.3 | 4.1 ± 0.5 | 4.1 ± 0.5 | 4.3 ± 0.3 | 2.4 ± 0.4 | 3.0 ± 0.6 | 2.7 ± 0.7 | 3.8 ± 0.7 |
| CD20+ | 22.4 ± 4.7 | 27.1 ± 3.5 | 28.7 ± 6.3 | 19.9 ± 4.5 | 22.4 ± 4.5 | 19.6 ± 2.7 | 20.0 ± 6.7 | 26.8 ± 6.4 |
| %CD20+CD69+ | 2.6 ± 0.4 | 3.5 ± 1.1 | 3.3 ± 0.5 | 2.6 ± 1.2 | 13.9 ± 1.8 | 13.2 ± 2.2 | 19.5 ± 2.9 | 13.5 ± 2.7 |
| CD20+CD32+ (MFI) | 56.2 ± 7.5 | 84.9 ± 15.5 | 71.2 ± 17.9 | 66.0 ± 11.3 | 72.2 ± 13.6 | 126.6 ± 13.8 | 65.2 ± 12.2 | 87.5 ± 13.4 |
NI, Non-infected macaques; CCC(-), Absence of Chronic Chagasic Cardiopathy; CCC(+), Mild Chronic Chagasic Cardiopathy; CCC(++), Moderate Chronic Chagasic Cardiopahty. Data are expressed as mean values (% or mean fluorescence intensity-MFI) standard error. Multiple comparisons amongst groups were carried out by Kruskal-Wallis test followed by Dunn’s post-test for sequential pairwise comparisons and significant differences at p < 0.05 depicted by letters “a”, “b”, “c” and “d” as compared to NI, CCC(-), CCC(+) and CCC(++), respectively. All significant differences are highlighted in bold format.